Rizzo, A. Et Al. 2024. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. FUTURE ONCOLOGY , no.20 , 1427-1434.

Rizzo, A., Rinaldi, L., Massafra, R., Cusmai, A., GÜVEN, D. C., Forgia, D. L., ... Latorre, A.(2024). Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes. FUTURE ONCOLOGY , no.20, 1427-1434.

Rizzo, Alessandro Et Al. "Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes," FUTURE ONCOLOGY , no.20, 1427-1434, 2024

Rizzo, Alessandro Et Al. "Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes." FUTURE ONCOLOGY , no.20, pp.1427-1434, 2024

Rizzo, A. Et Al. (2024) . "Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes." FUTURE ONCOLOGY , no.20, pp.1427-1434.

@article{article, author={Alessandro Rizzo Et Al. }, title={Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes}, journal={FUTURE ONCOLOGY}, year=2024, pages={1427-1434} }